5) * According to the third English edition of the Japanese Class

5) * According to the third English edition of the Japanese Classification of Gastric Carcinoma [4]. † According to the seventh edition of the International Union Against Cancer TNM guidelines [3]. Relationships between clinicopathological characteristics and nodal metastases are shown https://www.selleckchem.com/autophagy.html in Table 2. The only characteristic significantly associated with nodal metastases was lymphatic invasion in pT1b2 tumors. Table 2 Results of univariate analyses showing relationships between clinicopathological characteristics and lymph node metastases Variables

pT1a tumor (n = 161) pT1b1 tumor (n = 43) pT1b2 tumor (n = 123)   pN(+) p-value pN(+) p-value pN(+) p-value Total 4/161 (2.5%)   4/43 (9.3%)   37/123 (30.1%)      Sex   0.6269   0.2802   0.8309    Male 3/88 (3.4%)   4/28 (14.3%)   26/88 (29.6%)      Female 1/73 (1.4%)   0/15   11/35 (31.4%)   Age   0.6332   0.3449   0.8432    < 65 3/91 (3.3%)   3/21 (14.3%)   16/51 (31.4%)      65 ≤ 1/70 (1.4%)   1/22 (4.6%) Palbociclib ic50   21/72 (29.2%)   Main tumor site   0.1903   0.2707   0.1129    Upper 0/19   0/3   3/21 (14.3%)      Middle 4/89 (4.5%)   4/27 (14.8%)   17/59 (28.8%)      Lower 0/53   0/13   17/43

(39.5%)   Clinical macro type   0.5655   0.5579   0.4764    Depressed or excavated 3/131 (2.3%)   4/33 (12.1%)   27/96 (28.1%)      Flat or elevated 1/30 (3.3%)   0/10   10/27 (37.0%)   Pathological macro type   1.0000   1.0000   0.4764    Depressed 4/139 (2.9%)   4/37 (10.8%)   27/96 (28.1%)      Flat or elevated 0/22   0/6   10/27 (37.0%)   Ulceration   0.1287   0.3235   0.4200    No 0/72   1/23 (4.4%)   21/77 (27.3%)      Yes 4/89 (4.5%)   3/20 (15.0%)   16/46 (34.8%)   Main histologic type   0.1252   0.4672   0.8441    Differentiated 0/74   2/29 (6.9%)   19/66 (28.8%)      Undifferentiated 4/87 (4.6%)   2/14 (14.3%)   18/57 (31.6%)   Pathological tumor size   1.0000   1.0000   0.0589

   ≤20 mm 1/60 (1.7%)   0/7   4/28 (14.3%)      20 mm< 3/101 (2.5%)   4/36 (11.1%)   33/95 (34.7%)   Pathological tumor size   0.3083   1.0000   0.1730    ≤30 mm 1/96 (1.0%)   2/21 (9.5%)   13/55 (23.6%)      30 mm< 3/65 (4.6%)   2/22 (9.1%)   24/68 (35.3%)   Lymphatic invasion †   0.0731 L-NAME HCl   0.5227   < 0.0001**    L0 3/158 (1.9%)   3/36 (8.3%)   4/52 (7.7%)      L1-2 1/3 (33.3%)   1/7 (14.3%)   33/71 (46.5%)   Venous invasion †   1.0000   1.0000   0.4200    V0 4/160 (2.5%)   4/42 (9.5%)   21/77 (27.3%)      V1-3 0/1   0/1   16/46 (34.8%)   ** p < 0.01. † According to the seventh edition of the International Union Against Cancer TNM guidelines [3]. We combined pT1a (m) and pT1b1 (sm1) tumors into one group because the incidence of nodal metastases was under 10% in both, and compared relationships between histological types and nodal metastases in the pT1a-pT1b1 (m-sm1) and pT1b2 (sm2) groups (Table 3). A total of 45 out of 327 patients had nodal metastases, including 8 of the 204 patients in the pT1a-pT1b1 (m-sm1) group.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>